FXN and Friedreich ataxia: Here, to untangle the impact of FXN deficiency specifically in microglia and to disclose microglial contribution to disease pathogenesis in FRDA, we used iPSC-derived microglia (iMGs) from FRDA patients, related familial carriers and unrelated healthy donors and applied the previously reported CRISPR/Cas9 gene editing approach to explore its therapeutical potential in our experimental conditions.